{"title":"The role of inflammatory parameters in predicting acute complicated diverticulitis.","authors":"Fırat Canlıkarakaya, Serhat Ocaklı, İbrahim Doğan, Bedri Burak Sucu, Nurhak Cihangir Çınkıl","doi":"10.1080/17520363.2025.2517534","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Acute diverticulitis is an inflammatory process associated with pericolonic inflammation involving one or more colonic diverticula and is usually classified as uncomplicated or complicated.</p><p><strong>Method: </strong>This multicenter study retrospectively examined the data of 135 patients who received inpatient treatment for diverticulitis in two tertiary hospitals. Some inflammation scores were calculated with the data obtained from the patients' Complete blood count(CBC) and biochemical laboratory results, and the power of these scores in predicting complicated diverticulitis was examined.</p><p><strong>Results: </strong>A total of 135 patients (57 men and 78 women) were included in this study. In the ROC analysis performed to evaluate the effectiveness of predicting complications, the CRP/Albumin(CAR) score was found to be significant (AUC: 0.762, <i>p</i> = 0.001). For a cutoff value > 0.25, CAR predicted complications with 73% sensitivity and 76% specificity (AUC: 0.762, <i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>Determining the severity of the disease by differentiating complicated from uncomplicated cases will contribute to reducing hospital stay times and related costs. Our study showed that CAR score can be used as a reliable, inexpensive, and rapid marker for predicting complicated diverticulitis in acute diverticulitis.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"463-469"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2517534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Acute diverticulitis is an inflammatory process associated with pericolonic inflammation involving one or more colonic diverticula and is usually classified as uncomplicated or complicated.
Method: This multicenter study retrospectively examined the data of 135 patients who received inpatient treatment for diverticulitis in two tertiary hospitals. Some inflammation scores were calculated with the data obtained from the patients' Complete blood count(CBC) and biochemical laboratory results, and the power of these scores in predicting complicated diverticulitis was examined.
Results: A total of 135 patients (57 men and 78 women) were included in this study. In the ROC analysis performed to evaluate the effectiveness of predicting complications, the CRP/Albumin(CAR) score was found to be significant (AUC: 0.762, p = 0.001). For a cutoff value > 0.25, CAR predicted complications with 73% sensitivity and 76% specificity (AUC: 0.762, p = 0.001).
Conclusion: Determining the severity of the disease by differentiating complicated from uncomplicated cases will contribute to reducing hospital stay times and related costs. Our study showed that CAR score can be used as a reliable, inexpensive, and rapid marker for predicting complicated diverticulitis in acute diverticulitis.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
